Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and F...( Company Launches First-Ever Direc...)

Company Launches First-Ever Direct-To-Consumer Campaign of a Living

Cell-Based Therapy

CANTON, Mass., Feb. 11 /PRNewswire/ -- Organogenesis, Inc., the first company to successfully mass-produce living regenerative medicine products, is again breaking new ground by launching the first-ever direct-to-consumer (DTC) educational campaign for a living cell-based therapy. As the first bio-engineered living cell therapy to have received FDA approval, Apligraf(R) has been used successfully by doctors in treating hundreds of thousands of patients with diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) in the U.S. and around the world.

Direct-to-consumer ads are appearing in publications targeting diabetics and others prone to chronic venous leg ulcers and diabetic foot ulcers. The campaign will highlight the medical advances that have resulted in bio-active wound products like Apligraf, which is designed to "kick start" the body's natural healing process in these hard-to-heal wounds.

Organogenesis' comprehensive direct-to-consumer campaign also includes the launch of a new consumer educational web site, http://www.Apligraf.com, internet marketing, educational materials for patients and point-of-purchase features. The print ad can be viewed online at http://www.apligraf.com/offsite/pdf/apligraf_ad.pdf.

The campaign will focus on contrasting traditional wound care treatments, such as ointments and gauze dressings, versus living cell-based therapies, the latest innovation in wound healing. The majority of DFU and VLU patients are being treated with traditional and often ineffective wound care therapies for these severe and chronic wounds, and most are still unaware of the advanced treatment options.

"Non-healing wounds are common with diabetics and people with circulator
'/>"/>